Inclusion Criteria:

- Age >=18 years, either sex, any race.

- Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

- There must be no known standard therapy, or disease must be refractory to standard
therapy

- Adequate hematologic, renal, and hepatic organ function and laboratory parameters

- For advanced solid tumors, non-Hodgkin's lymphoma, or multiple myeloma:

- Participants must have histologically proven solid tumors, non-Hodgkin's
lymphoma, or multiple myeloma.

- Evaluable malignancy must be present by computed tomography or magnetic
resonance imaging, obtained within 4 weeks prior to the start of treatment with
SCH 727965.

- Subjects with multiple myeloma must have measurable disease defined as:

- Serum monoclonal protein greater than 0.5 g/dL or urine light chain excretion of
greater than 0.2 g/24-hour obtained within 4 weeks prior to the start of
treatment.

- Participants with lower M protein values or nonsecretory myeloma are eligible if
measurable disease can be established within 4 weeks prior to start of
treatment, such as:

- serum free light chain ratio greater than 5 times the normal ratio limit;
and/or

- measurable soft tissue plasmacytoma greater than 2 cm, by either physical
examination and/or applicable radiographs; and/or

- bone marrow involvement greater than 30%.

- For B-cell chronic lymphocytic leukemia (B-CLL):

- Diagnosis of B-CLL according to the National Cancer Institute Working Group
(NCI-WG) criteria or a histological diagnosis of small lymphocytic lymphoma.

- Disease must be evaluable according to NCI-WG response criteria.

Exclusion Criteria:

- Symptomatic brain metastases or primary central nervous system malignancy.

- Previous radiation therapy to >25% of the total bone marrow.

- Previous treatment with SCH 727965.

- Known HIV infection.